SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Procter & Gamble Co. engages in the provision of branded consumer packaged goods. It operates through the following segments: Beauty, Grooming, Health Care, Fabric and Home Care, and Baby, Feminine and Family Care. The Beauty segment offers hair, skin, and personal care. The Grooming segment consists of shave care like female and male blades and razors, pre and post shave products, and appliances. The Health Care segment includes oral care products like toothbrushes, toothpaste, and personal health care such as gastrointestinal, rapid diagnostics, respiratory, and vitamins, minerals, and supplements. The Fabric and Home care segment consists of fabric enhancers, laundry additives and detergents, and air, dish, and surface care. The Baby, Feminine and Family Care segment sells baby wipes, diapers, and pants, adult incontinence, feminine care, paper towels, tissues, and toilet paper. The company was founded by William Procter and James Gamble in 1837 and is headquartered in Cincinnati, OH.

Procter & Gamble Co.

Procter & Gamble is trending as investors assess its recent earnings beat and future guidance, with some analysts predicting multiple price target raises. Community members are actively discussing the company's strong brands and potential for long-term growth, as well as concerns about tariff headwinds and the impact of a potential CEO change. Despite these challenges, many see $PG as a reliable defensive stock, especially as it approaches its ex-dividend date.

Click Holdings Ltd. operates as a holding company which provides temporary and permanent personnel solutions. Its services include professional solution services, nursing solution services, and logistics and other solution services. The company was founded by Chan Chun Sing on January 31, 2024 and is headquartered in Hong Kong.

Click Holdings Ltd. - Ordinary Shares - Class A

Click Holdings Limited

Click Holdings is trending as traders discuss its potential for a significant run, citing its small float and high insider ownership. Community members are drawing comparisons to past high-flying stocks and anticipating a strong opening. Bullish sentiment seems to be fueled by news, with some cautioning about potential pullbacks.

Picard Medical, Inc. is a medical technology company, which manufactures and sells the only U.S. FDA, and Health Canada approved implantable SynCardia TAH. It develops the first fully implantable SynCardia TAH as an alternative to heart transplantation for patients with biventricular heart failure in the U.S. and around the world. The company is headquartered in Tucson, AZ.

Picard Medical Inc.

PMI is trending with increased after-hours activity and high trading volume as the community debates whether a large drop in price creates a buying opportunity. Community members are analyzing the company's recent statement addressing stock volatility and are discussing potential dilution impacts, as well as its long-term value. Some traders point to technical indicators suggesting a potential rebound, while others caution against a possible pump-and-dump scenario.

Neuphoria Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing therapies that address the complex needs of individuals affected by neuropsychiatric disorders. It focuses on developing BNC210, an oral drug designed for the acute treatment of social anxiety disorder (SAD) and the chronic treatment of post-traumatic stress disorder (PTSD) by selectively targeting the a7 nicotinic acetylcholine receptor. The company was founded on December 23, 2024 and is headquartered in Burlington, MA.

Neuphoria Therapeutics Inc.

NEUP is trending due to a surge in price and volume, potentially fueled by recent insider buying and milestone payments from Merck related to their Alzheimer's program. The community is actively discussing the stock's low float and the potential for a short squeeze, with some traders speculating about a run to double digits. However, some traders also caution about potential dilution.

Coinbase Global, Inc. engages in the provision of a trusted platform that serves as a compliant on-ramp to the onchain economy and enables users to engage in a wide variety of activities with their crypto assets in both proprietary and third-party product experiences enabled by access to decentralized applications. It offers consumers primary financial account for the cryptoeconomy, institutions a full-service prime brokerage platform with access to deep pools of liquidity across the crypto marketplace, and developers a suite of products granting access to build onchain. The company was founded by Brian Armstrong and Fred Ernest Ehrsam in May 2012 and is headquartered in New York, NY.

Coinbase Global Inc - Ordinary Shares - Class A

Coinbase Global Inc

Coinbase ($COIN) is trending following an upgrade from J.P. Morgan, with community members discussing potential revenue streams and the Base blockchain's future. Bullish traders anticipate a run-up to earnings, while others express concern over crypto market volatility and its impact on the stock. Some investors mention holding their Bitcoin on Coinbase, emphasizing the importance of prediction markets/US equities being added to the platform.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan is trending as investors analyze potential market corrections after the CEO's warning about elevated asset prices and geopolitical tensions. Community members are closely watching for a break above key resistance levels, while also assessing the impact of potential interest rate cuts on the financial sector. Discussions also involve JPMorgan's ventures into crypto and quantum computing.

The $ROSIE project centers around a unique, AI-powered memecoin inspired by "Rosie the Robot," a beloved character known for her role as a caring, motherly robot in popular culture. The purpose of $ROSIE is twofold: entertainment through an interactive AI feature and social impact via charitable donations.  Users can interact with an AI version of Rosie on the project’s website, where they can ask questions and engage in conversations. The utility of $ROSIE goes beyond typical memecoins by enabling users to donate tokens, which will be directed towards charitable causes supporting mothers. Through this initiative, the project combines the viral appeal of meme tokens with meaningful contributions to social causes, while leveraging AI technology to create a novel user experience.

Rosie the Robot

Rosie the Robot (ROSIE) is gaining attention, with the community highlighting its potential and bullish sentiment. The token appears to be associated with the Solana blockchain, as indicated by the ticker $SOL. Investors are anticipating future growth for this token.

Welcome to SLAP – The Only Coin That Slaps Harder Than Your Moms  Tired of coins that claim they SLAP but are nothing but limp wrists? SLAP is here to SLAP some sense into the crypto space.  Founded by the Flutter of Five Fingers and powered by the Prancing of the Pried Palm, SLAP isn’t just another coin—it’s an attitude.  We’re not here to talk roadmaps, utility, or world peace. We’re here to SLAP charts, SLAP the haters, and SLAP our way to the top. No VC suits, no corporate nonsense—just raw, unfiltered internet culture with a side of “did we just do that?  ”So load your wallet, mute your financial advisor, and get ready to ride the most unhinged meme rocket. Open up your hands, and start swingin'. You never know what you could hit.  SLAP: It’s not a coin. It’s a lifestyle.

Slap

SLAP is trending as community members rally around the project's real-world utility and partnerships, including sponsored athletes and events. The community emphasizes the project's grindset mentality and commitment to building, drawing attention to its active presence and growth. With the rise of other cryptocurrencies, traders are suggesting that SLAP will continue to grow with the rest of the market.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Compute and Networking Business Unit (CNBU), Mobile Business Unit (MBU), Embedded Business Unit (EBU), and Storage Business Unit (SBU). The CNBU segment includes memory products and solutions sold into client, cloud server, enterprise, graphics, and networking markets. The MBU segment is involved in memory and storage products sold into smartphone and other mobile-device markets. The EBU segment focuses on memory and storage products sold into automotive, industrial, and consumer Markets. The SBU segment consists of SSDs and component-level solutions sold into enterprise and cloud, client, and consumer storage markets. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Micron Technology is trending due to optimism around memory demand and pricing, particularly related to AI applications, with analysts raising price targets. The community is discussing the stock's potential for further gains, citing strong earnings growth and a relatively low P/E ratio compared to other AI-related stocks. Some are also noting its role as a key supplier in the AI supply chain.

Huntington Ingalls Industries, Inc. engages in the shipbuilding business. It operates through the following business segments: Ingalls, Newport News, and Mission Technologies. The Ingalls segment designs and constructs non-nuclear ships, including amphibious assault ships, expeditionary warfare ships, surface combatants, and national security cutters (NSC). The Newport News segment designs and builds nuclear-powered aircraft carriers and submarines, and the refueling and overhaul and the inactivation of nuclear-powered aircraft carriers. The Mission Technologies segment includes business groups focused on high-end information technology (IT) and mission-based solutions for DoD, intelligence, and federal civilian customers, life-cycle sustainment services to the U.S. Navy fleet and other maritime customers, unmanned, autonomous systems, and nuclear management and operations and environmental management services for the Department of Energy (DoE), DoD, state and local governments, and private sector companies. The company was founded on August 4, 2010 and is headquartered in Newport News, VA.

Huntington Ingalls Industries Inc

Huntington Ingalls is trending amid discussions about the potential for increased shipbuilding as a countermeasure to China's growing naval power, as well as a possible Merchant Marine fleet expansion. Community members are also weighing the company's strong market position against its current valuation, noting that while it's a solid company, the present price might not be attractive for new investors. Some traders are eyeing potential Korean and Japanese partnerships.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Autonomix Medical, Inc. (AMIX) Upgraded to Strong Buy: Here's Why

Autonomix Medical, Inc. (AMIX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

AMIX Stock May Climb Following Key U.S. Patent for Nerve-Sensing Tech

Monte Rosa Therapeutics Inc. (<a class="mention" data-mention="$GLUE" data-symbol-id="GLUE" href="https://stocktwits.com/symbol/GLUE" target="_blank">$GLUE</a>)<figure class="image"><a href="https://stocktwits.com/symbol/GLUE"><img style="aspect-ratio:1284/287;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132438_e581646ba1.png" alt="Screenshot 2024-10-28 132438.png" width="1284" height="287"></a><figcaption>Monte Rosa Therapeutic's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Monte Rosa Therapeutics surged over 130% on Monday, reaching a two-year high of $12.15 after&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/glue-stock-enthralls-retail-with-novartis-licensing-deal/cJ2rnM9RJW">announcing an exclusive global licensing agreement with Novartis AG ($NVS).</a>&nbsp;The collaboration focuses on developing innovative treatments for immune-related conditions, particularly MRT-6160, an oral drug designed to inhibit the degradation of VAV1, a key signaling protein for T and B cell receptors.&nbsp;As part of the agreement, Novartis will pay $150 million upfront for exclusive worldwide rights to MRT-6160 and other VAV1-targeting molecular glues, with Monte Rosa eligible for up to $2.1 billion in milestones and tiered royalties on international sales.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with ‘extremely high’ (97/100) message volume.Evoke Pharma Inc. (<a class="mention" data-mention="$EVOK" data-symbol-id="EVOK" href="https://stocktwits.com/symbol/EVOK" target="_blank">$EVOK</a>)<figure class="image"><a href="https://stocktwits.com/symbol/EVOK"><img style="aspect-ratio:1282/282;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132459_473ee74b09.png" alt="Screenshot 2024-10-28 132459.png" width="1282" height="282"></a><figcaption>Evoke Pharma's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Evoke Pharma’s shares were up over 30% on Monday following its presentation of&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/evoke-pharma-stock-spikes-higher-on-study-data/cJ2rllaRJO">positive data for its lead drug</a>, Gimoti, as a treatment option for diabetes gastroparesis.The company ranked among the top 10 trending stocks on Stocktwits, secured the second spot for most watched, and was listed in the top 20 most active stocks&nbsp;on Monday afternoon.Evoke Pharma and its partner, Eversana, found that patients using Gimoti, a nasal version of metoclopramide, experienced significant improvements compared to those using the oral formulation. Patients who received the nasal treatment had reduced healthcare resource use and fewer healthcare visits.Retail sentiment on Stocktwits surged into ‘extremely bullish’ territory (97/100) with ‘extremely high’ (97/100) message volume.Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>)<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1271/277;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_132518_8d6392edf1.png" alt="Screenshot 2024-10-28 132518.png" width="1271" height="277"></a><figcaption>Autonomix Medical's sentiment meter as of 1:25 p.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Shares of Autonomix skyrocketed by more than 90% on Monday morning following the&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/autonomix-stock-rallies-on-strong-trial-results/cJ2rlAHRJf">announcement of positive results from its clinical trial</a> aimed at alleviating pain in pancreatic cancer patients.&nbsp;The stock became the second-highest trending on Stocktwits, just behind Trump Media &amp; Technology Group Corp. ($DJT), and was listed among the top 10 most watched stocks of the day.Retail sentiment on Stocktwits surged to ‘extremely bullish’ (97/100) with chatter escalating into ‘extremely high’ (97/100) territory.For updates and corrections email newsroom@stocktwits.com.Read more: <a href="https://stocktwits.com/news-articles/markets/equity/mstr-stock-hits-all-time-high-as-btc-crosses-68000/cJ2rj2hRJ9">MicroStrategy’s Bitcoin Holdings Drive Historic High: Retail Unfazed</a>

Retail is most bullish on these stocks today | Source: Pexels

Monte Rosa Therapeutics, Evoke Pharma, and Autonomix Medical: The Top 3 Stocks Capturing Retail Attention

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.

Equity

Retail sentiment was particularly strong for healthcare stocks today, as Monte Rosa, Autonomix, and Evoke Pharma each announced positive developments regarding their respective innovations.


Shares of Autonomix Medical Inc. (<a class="mention" data-mention="$AMIX" data-symbol-id="AMIX" href="https://stocktwits.com/symbol/AMIX" target="_blank">$AMIX</a>) soared by over 90% on Monday morning after the company reported positive results from its clinical trial focused on managing pain in pancreatic cancer patients.It ranked as the second-highest trending stock on Stocktwits on Monday, trailing only Trump Media &amp; Technology Group Corp. (<a class="mention" data-mention="$DJT" data-symbol-id="DJT" href="https://stocktwits.com/symbol/DJT" target="_blank">$DJT</a>), and was also among the top 10 most watched stocks.The trial employs an innovative technique to target and ablate the nerves responsible for pain in late-stage pancreatic cancer patients.&nbsp;Early results from the first five participants, known as the "lead-in" cohort, have been promising, with all reporting significant pain relief after the procedure.Set to conclude by the end of 2024, the trial seeks to provide an alternative to opioid pain management, which poses risks of addiction and overdose.Autonomix's technology features a catheter-based microchip sensing array antenna, which can detect neural signals more sensitively than current technologies. This precision-guided approach is intended to diagnose and treat issues related to the peripheral nervous system.To further enhance the trial, the company plans to enroll 20 additional patients, focusing on those experiencing higher levels of pain.<figure class="image"><a href="https://stocktwits.com/symbol/AMIX"><img style="aspect-ratio:1285/291;" src="https://st-everywhere-cms-prod.s3.us-east-1.amazonaws.com/Screenshot_2024_10_28_103029_e257a3d1ef.png" alt="Screenshot 2024-10-28 103029.png" width="1285" height="291"></a><figcaption>Autonomix Medical's sentiment meter as of 10:30 a.m. ET on Oct. 28, 2024 | Source: Stocktwits</figcaption></figure>Retail sentiment on Stocktwits shot up to ‘extremely bullish’ (89/100) from ‘neutral’ a day ago accompanied by ‘extremely high’ (92/100) chatter.&nbsp;On Thursday last week, Autonomix completed a 1-for-20 reverse stock split. Every 20 shares were combined into one share, reducing the total number of outstanding shares from about 23 million to around 1.15 million.Autonomix’s stock has been struggling since its listing in February, earlier this year. It saw highs of $152 and has since lost 86% of its value.For updates and corrections email newsroom@stocktwits.com.Read more:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/biontech-stock-falls-after-fda-concerns/cJ22FLsRIs">BioNTech Stock Dips On FDA Concerns Over Cancer Drug Trial: Retail Response Mixed</a>

Autonomix Medical reported positive preliminary results from its ongoing proof-of-concept human clinical trial. | Source: Pexels

Autonomix’s Stock Rallies on Strong Trial Results: Retail Sentiment Soars

Autonomix’s stock has been struggling since its listing in February, earlier this year. It saw highs of $152 and has since lost 86% of its value. Monday’s surge in share price comes after the company completed a 1-for-20 reverse stock split on Thursday.

Autonomix to Present at the MedInvest Biotech & Pharma Investor Conference

Live webcast presentation on Thursday, April 4th at 3:55 PM ET THE WOODLANDS, TX, March 27, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ( Autonomix or the Company ), a...

Autonomix (NASDAQ: AMIX) to Present at the Benzinga Virtual Healthcare Summit 2024

Live webcast presentation on Wednesday, March 20th at 11:50 AM ET THE WOODLANDS, TX, March 20, 2024 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) ( Autonomix or the Company ), a...

Autonomix Appoints Jennifer Cook as Chief Business Officer

Autonomix Medical, Inc.

 Mrs. Jennifer Cook

Proven executive with 28 years of success building winning B2C & B2B businesses, brands, and teams for premier consumer, healthcare...

Autonomix Completes First Three Patient Procedures in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 14, 2024 (GLOBE NEWSWIRE...

Autonomix Enrolls First Patients in Human Clinical Trial Targeting Multi-Billion-Dollar Pancreatic Cancer Market

First trial to ever evaluate radiofrequency (RF) ablation in a transvascular approach to reduce the pain associated with pancreatic cancer THE WOODLANDS, TX, March 06, 2024 (GLOBE NEWSWIRE...

Autonomix Signs Key Clinical Agreements in Preparation to Begin March 2024 Human Clinical Trial

Proof-of-concept (PoC) human clinical trial targeting multi-billion-dollar pancreatic cancer market through transvascular RF ablation Agreements represent final steps needed in order to commence...

Autonomix Medical, Inc. is a development stage medical device development company focused on advancing innovative technologies for sensing and treating disorders relating to the nervous system. Its technology platform includes a catheter-based microchip-enabled array that can detect and differentiate neural signals with a high degree of sensitivity as demonstrated in animal studies. The company was founded by Robert Schwartz, Landy Toth, David A. Robins, and Robert A. Van Tassel on June 10, 2014 and is headquartered in The Woodlands, TX.

Autonomix Medical Inc.

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

Current Price	N/A
Prev Close	N/A
Open	N/A
Dividend Yield	0.00%
50-Day Moving Average	$1.12
Beta	0.76
Avg. Volume	466,425.95
PE Ratio	-0.18

52-Week High	$21.49
52-Week Low	$0.9612
Market Capitalization	$6.94M
EPS (Annual)	-$6.46
Price to Book	0.64
Revenue Per Employee	$0.00
Enterprise Value/EBITDA	N/A

AMIX
Autonomix Medical Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest AMIX News

AMIXAutonomix Medical Inc.